Payment overview · 2025
General Payments
$741.58
15 reported records · 6 companies
Healthcare provider profile · identity verified
Om Dutt Sharma, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ENGLEWOOD, FL · NPI 1497798342
Verified facts
What the public records show
CMS Open Payments records show Om Dutt Sharma, M.D. received $741.58 in general payments during 2025 across 15 reported records.
AstraZeneca Pharmaceuticals LP accounted for 62.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Mounjaro by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $460.39 | 62.1% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $125.00 | 16.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $66.30 | 8.9% | 3 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $37.39 | 5.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.50 | 3.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.00 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $724.20 | 14 |
| Education | $17.38 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $200.47 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $191.68 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $181.76 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $66.30 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $66.30 | 3 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $37.39 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $28.50 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $20.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 209 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 33 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
209 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 881 | 243 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 621 | 191 |
| Amlodipine Besylate | Amlodipine Besylate | 546 | 156 |
| Levothyroxine Sodium | Levothyroxine Sodium | 495 | 133 |
| Metoprolol Succinate | Metoprolol Succinate | 437 | 118 |
| Lisinopril | Lisinopril | 434 | 123 |
| Omeprazole | Omeprazole | 379 | 117 |
| Pantoprazole Sodium | Pantoprazole Sodium | 350 | 108 |
| Alprazolam | Alprazolam | 307 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 305 | 81 |
| Losartan Potassium | Losartan Potassium | 294 | 85 |
| Escitalopram Oxalate | Escitalopram Oxalate | 287 | 91 |
| Gabapentin | Gabapentin | 255 | 66 |
| Metformin Hcl | Metformin Hcl | 241 | 67 |
| Simvastatin | Simvastatin | 241 | 67 |
| Clopidogrel | Clopidogrel Bisulfate | 217 | 61 |
| Eliquis | Apixaban | 209 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 194 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 187 | 50 |
| Montelukast Sodium | Montelukast Sodium | 177 | 64 |
| Furosemide | Furosemide | 173 | 50 |
| Glimepiride | Glimepiride | 172 | 52 |
| Prednisone | Prednisone | 160 | 94 |
| Allopurinol | Allopurinol | 155 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 155 | 52 |
| Potassium Chloride | Potassium Chloride | 149 | 46 |
| Sertraline Hcl | Sertraline Hcl | 146 | 41 |
| Celecoxib | Celecoxib | 140 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 140 | 42 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 134 | 80 |
| Temazepam | Temazepam | 134 | 35 |
| Alendronate Sodium | Alendronate Sodium | 124 | 39 |
| Telmisartan | Telmisartan | 124 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 122 | 44 |
| Azithromycin | Azithromycin | 121 | 102 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 117 | 31 |
| Meloxicam | Meloxicam | 114 | 35 |
| Carvedilol | Carvedilol | 106 | 26 |
| Donepezil Hcl | Donepezil Hcl | 102 | 22 |
| Finasteride | Finasteride | 97 | 26 |
| Spironolactone | Spironolactone | 97 | 28 |
| Paroxetine Hcl | Paroxetine Hcl | 93 | 25 |
| Ezetimibe | Ezetimibe | 92 | 26 |
| Trazodone Hcl | Trazodone Hcl | 91 | 26 |
| Lorazepam | Lorazepam | 87 | 24 |
| Mirtazapine | Mirtazapine | 87 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 78 | 31 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 69 | 19 |
| Atenolol | Atenolol | 67 | 18 |
| Memantine Hcl | Memantine Hcl | 65 | 12 |
| Cephalexin | Cephalexin | 59 | 36 |
| Valsartan | Valsartan | 59 | 19 |
| Famotidine | Famotidine | 57 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 56 | 26 |
| Xarelto | Rivaroxaban | 56 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 55 | 17 |
| Mounjaro | Tirzepatide | 54 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 50 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 49 | 17 |
| Solifenacin Succinate | Solifenacin Succinate | 48 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 46 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 31 |
| Synthroid | Levothyroxine Sodium | 44 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | 17 |
| Ibuprofen | Ibuprofen | 43 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 13 |
| Glipizide Er | Glipizide | 41 | 11 |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Pregabalin | Pregabalin | 38 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 36 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Glipizide | Glipizide | 34 | suppressed |
| Hydrocortisone | Hydrocortisone | 34 | 23 |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Bumetanide | Bumetanide | 33 | suppressed |
| Clonazepam | Clonazepam | 33 | 11 |
| Farxiga | Dapagliflozin Propanediol | 33 | 13 |
| Jardiance | Empagliflozin | 33 | suppressed |
| Ozempic | Semaglutide | 33 | suppressed |
| Sotalol | Sotalol Hcl | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | 12 |
| Diazepam | Diazepam | 32 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 19 |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Estradiol | Estradiol | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 17 |
| Lactulose | Lactulose | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 13 |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Multaq | Dronedarone Hcl | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 16 | 13 |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | 13 |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $741.58 · 15 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Arikayce, BREZTRI, Brinsupri, ELIQUIS, FARXIGA, JARDIANCE, Kerendia, NURTEC ODT, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error